Summary Malignant progression of tumour cells is caused by the accumulation of genetic defects, which when combined will generate a large phenotypic diversity. Simultaneous quantitation of a large number of gene products in tumour cells is desirable, but difficult to achieve. We have here quantitated the levels of a number of abundant polypeptides in human breast carcinoma cells using two-dimensional gel electrophoresis (2-DE; PDQUEST). For this purpose, tumour cells were prepared from the tissue of 17 breast carcinomas. Fibroadenoma tissue was used as reference for benign cells. An increase of the spot density of the PCNA polypeptide was observed in rapidly proliferating tumour cells, confirming the validity of the procedures used. In the set of 24 polypeptide spots with known identity, decreases in cytokeratin and tropomyosin levels were observed. The levels of all cytokeratin forms resolved (CK7, CK8, CK15 and CK18) were significantly lower in carcinomas than in fibroadenomas. The levels of tropomyosin 2 and 3 were lower in carcinomas than in fibroadenomas. In contrast, the levels of some members of the stress protein family (pHSP60, HSP90 and calreticulin) were higher in carcinomas. Furthermore, changes in the expression of lactate dehydrogenase and GT-i, but not in nm23, were observed. We conclude that simultaneous analysis of multiple polypeptides in human carcinomas can be achieved by 2-DE and may be useful in prognostic studies, and that malignant progression of breast carcinomas results in the decreased expression of cytokeratin polypeptides. This phenomenon must be considered in studies where cytokeratins are used as markers to identify the epithelial cell compartment in breast carcinomas.
Breast cancer is both biologically and clinically a heterogeneous disease. Although presenting without evidence of disseminating cancer, a proportion of women will die rapidly in metastatic disease. In spite of enormous efforts in breast cancer research, three main problems remain: (1) to objectively and reliably select those premalignant lesions which, if untreated, will progress to invasive malignancy; (2) to objectively and reliably determine the aggressiveness of an individual tumour and (3) to analyse cellular properties which allow highly individualised tumour-specific treatment.
Two-dimensional gel electrophoresis (2-DE) is a technique which can be used to obtain qualitative and quantitative information on protein expression in cells. In a recent update of the two-dimensional protein database, 1082 proteins were reported to be identified by name (Celis et al., 1995) . Identification is aided by recent progress in microsequencing, including mass spectrophotometry. We have here explored 2-DE to characterise polypeptide profiles in human breast carcinomas. Major polypeptides in the gel profiles were identified (mostly cytoskeletal and stress-related proteins) and quantified. We describe alterations in the expression of some of these polypeptides. We show that the levels of several cytokeratin polypeptides are lower in carcinomas than in fibroadenomas. These results suggest that 2-DE can be a valuable future tool for the characterisation of gene expression in human malignant tumours.
Materials and methods Tumour tissue samples All samples, described in Table I , were obtained shortly after resection and processed essentially as described below Correspondence: B Franzen Received 18 March 1996; revised 14 June 1996; accepted 2 July 1996 (Franzen et al., 1993) . Cells were purified from non-necrotic tumour tissue within 40 min after resection, and all steps were performed on ice in the presence of protease inhibitors.
Each resected tumour was placed on ice, cut in the middle and one (or two) macroscopically representative and nonnecrotic area was selected for extraction of cells. The surface of a freshly cut tumour was scraped with the dry blade of a sharp scalpel. As previously discussed, tumour cells are more loosely attached to the extracellular matrix than normal cells and will be preferentially extracted. Cells were collected in 1-2 ml of ice-cold medium (RPMI-1640) supplemented with 5% calf serum/protease inhibitors (0.2 mM phenylmethylsulphonyl fluoride and 0.83 mM benzamidine). Cell suspensions were first filtered using a 250 ,im filter directly followed by a 100 jMm nylon mesh to remove tissue fragments. Cell suspensions were then collected in new tubes and carefully underlaid with 1.0-1.5 ml of ice-cold Percoll phosphatebuffered saline (PBS) solution (54.7%, density 1.07 g ml-1) and finally centrifuged for 10 min at 1000 g and 4°C. The interface cell layers were washed with PBS and pelleted. The wet weight of each cell pellet was recorded and cells were then stored at -80°C. The final preparation of cell pellets was performed according to Linder et al. (1979) and Garrels et al. (1979) , with some modifications (Franzen et al., 1993) . Adjacent material was fixed in 4% buffered formalin and embedded in paraffin.
Characterisation offormalin-fixed specimens Malignant tumours were subdivided into two subgroups on the basis of proliferative index and DNA ploidy assessments. Proliferation index was determined by immunohistochemical staining using the MIB-1 antibody (Immunotech). The fraction of positive cells was scored and classified as 'low' (<20%), 'intermediate' (20-50%) and 'high' (>50%).
Histopathology (using haematoxylin-eosin-stained sections) was performed by one experienced pathologist and classified according to WHO. The nuclear DNA content was assessed using image cytometric analysis of Feulgen-stained GT(7r) . Cytokeratins were extracted from MCF-7 cell lysates (Paulin et al., 1980) . Proliferating cell nuclear antigen (PCNA) was identified by immunoblotting (PC1O MAb, Dakopatt) using a semi-dry system (Multiphor II Nova Blot, Pharmacia Biotech AB) and electrochemiluminescence detection (Amersham).
Scanning and image analysis 2-DE gels were scanned at 100 gm resolution using Molecular Dynamics laser densitometer. Data were analysed using the PDQUEST software (Garrels et al., 1984) (Pharmacia Biotech, Uppsala, Sweden). A synthetic 'identification reference pattern' including at least all identified spots was constructed. In subsequent analyses, polypeptide spots were matched to spots in the reference pattern using the PDQUEST software (construction of a 'matchset'). Background was subtracted, peaks located and the individual polypeptide quantities were expressed as p.p.m. of the total integrated optical density. Three groups were constructed within the matchset: benign lesions, DNA-diploid/lowproliferative tumours and DNA-aneuploid/high-proliferative tumours. The level of polypeptide expression in each group was calculated as the mean value (+standard deviation) of normalised p.p.m. values. We used the Mann-Whitney nonparametric test for determination of significant differences at the levels of P<0.05.
Results
Analysis of polypeptide expression in breast cancer lesions A total of 23 lesions were examined. Of these, six cases were non-malignant (four fibroadenomas) and 17 cases were invasive, ductal breast carcinomas (Table I) . Carcinomas were divided into two groups: (1) slowly proliferating and diploid tumours and (2) rapidly proliferating and aneuploid tumours as described in Materials and methods. The histopathological characteristics of all cases are presented in Table I . Cases not conforming to this classification were not considered.
Cells were extracted from fresh tumour tissue and single-cell suspensions free of erythrocytes were prepared as previously described (Franzen et al., 1993 ; see Materials and methods). These preparations were usually > 90% tumour cells. Samples were prepared for two-dimensional gel electrophoresis (2-DE). The polypeptide patterns were analysed by PDQUEST software (Garrels et al., 1984) , and the levels of individual polypeptides were expressed as p.p.m. The identity of individual spots was ascertained by co-electrophoresis of purified polypeptides and/ or matching with databases (see Material and methods). Shown in Figure 1 is a 'reference pattern' assembled from tumours and one breast cancer cell line (MDA-MB-23 1).
Evaluation of 2-DE gels from non-malignant and malignant breast lesions Figure 2 shows representative examples of gels derived from a fibroadenoma, a slowly proliferating carcinoma and a rapidly proliferating carcinoma. A 'window' of neutral to acidic proteins in the 25-100 kDa range is shown. Differences in polypeptide expression will be discussed below for various polypeptides of which the identities are known (encircled in Figures 1 and 2) . Mean values of spot intensities in different groups of lesions are presented in Table II. Cell cycle-related proteins The recorded spot intensity of PCNA (proliferating cell nuclear antigen) was found to reflect the proliferative status of the tumours. PCNA levels were 4.3-fold higher (significant, see Materials and methods) in highly malignant tumours than in non-malignant cells (Table II) . The distribution of PCNA levels (0.61) in various samples is shown in Figure 3 . Opl8 (oncoprotein 18/ stathmin) is a phosphoprotein believed to have a regulatory role in the cell cycle. Opl8 could not be detected in eight out of nine slowly proliferating/diploid tumours, but was detected in five out of eight rapidly proliferating/aneuploid tumours (Figure 3 ). Higher Opi8 levels were found in non-malignant lesions than in slowly proliferating carcinomas (Table II) .
Cytoskeletal proteins A number of cytoskeletal proteins were identified in the polypeptide maps. These include actin, tropomyosin 1 -5, aactinin, a-and f-tubulin and cytokeratins 7, 8, 15 and 18. Some of these proteins were not well resolved from neighbouring spots, others could not be quantified because of overstaining. The identity of cytokeratin 8 and 18 could be confirmed by extracting cytoskeletal polypeptides from MCF-7 breast carcinoma cells (Figure 4) . Cytokeratins 7 and 15 were tentatively identified by their (1) migration properties (spot position), (2) absence in fibroblasts, and (3) enrichment in cytoskeletal fractions from tumours. Tumour cytoskeleton preparations were, however, contaminated by cytosolic proteins, and the identification of cytokeratins 7 and 15 is considered as tentative. Cytokeratin 19 was identified using the MCF-7 extract but was not included in the analysis because of possible comigration with a large number of neighbouring spots in most of the cases.
All four forms of cytokeratins resolved were found to be expressed at lower levels (significant) in carcinomas than in fibroadenomas (Table II) . The levels of cytokeratin 8 and 18 in individual tumours is shown in Figure 4 . In 12 out of 17 carcinomas, cytokeratin 18 could not be detected due to low expression.
Tropomyosin levels were lower in carcinomas than in nonmalignant cells, confirming our previous findings (Franzen et al., 1996) . In the material analysed here, the decreases in tropomyosin 2 and 3 were statistically significant, but not that of tropomyosin 1. Non-Low-Highmal. prolif. prolif.
OP18
Non-Low-Highmal. prolif. prolif. Stress proteins Overexpression of some stress proteins, such as HSP90 and HSP27, have been associated with malignancy. We noticed a moderate increase in HSP90 (1.6-fold) and calreticulin (1.7-fold) in highly malignant cancers. HSP27 levels did not, in contrast, differ between carcinomas and nonmalignant cells. Whereas the levels of HSP60 showed small variations (1.3-fold higher in rapidly proliferating carcinomas), the levels of the phosphorylated form of this gene product, pHSP60, were 2.2-fold increased in rapidly proliferating carcinomas. This increase was statistically significant. nm23 nm23 (Nucleotide diphosphate kinase) levels have been reported to be low in metastatic cells (Steeg et al., 1993) . A weak, but not significant, increase in nm23 levels was preferentially recorded in slow proliferating carcinomas. In the material analysed here, we could not find any association with lymph node status.
Glutathione S-transferase 7t GT-7r has been implicated in tumour progression and in resistance to chemotherapy (Daniel et al., 1993) . In the material studied here, GT-7 levels were somewhat lower in malignant cells than in fibroadenomas. This difference was not statistically significant.
Constitutively expressed proteins
The levels of a number of identified proteins did not differ (less than 50% change) between groups. Mitcon3 (mitochondrial), eIF5A (initiation factor SA), LDH (lactate dehydrogenase form M), annexin V and EFlb (elongation factor 1I belonged to this category.
Discussion
Analysis of polypeptide profiles in human tumours is not a trivial task. Samples may contain relatively large amounts of protein from other cell types present in the tumours, such as stromal fibroblasts and lymphocytes. Furthermore, massive contamination by serum proteins may preclude large areas of the maps. These problems can be circumvented by purifying viable tumour cells from freshly excised tumours (Franzen et al., 1993) . We have studied here the expression of 24 polypeptides with known identity (by name) in breast carcinomas and show that changes in the levels of some of these polypeptides can be demonstrated. As more than 1000 polypeptides have been identified in the human 2-DE map (Celis et al., 1995) , it will be possible to make detailed characterisations of changes in gene expression in tumours in the future.
Tumours were classified as slowly proliferating/diploid or rapidly proliferating/aneuploid. Using this classification, we were convinced that the procedures used were sufficiently accurate to detect changes in the levels of proliferation markers. The levels of the PCNA polypeptide were found to increase in parallel with progression from non-malignant lesions to slowly proliferating and then to rapidly proliferating carcinomas. Similarly, oncoprotein 18 levels were 3-fold higher in rapidly growing tumours than in fibroadenomas.
Trask et al. (1990) reported that normal cultured breast epithelial cells produce cytokeratin 5, 6, 7, 14 and 15, whereas tumour cells produce mainly cytokeratin 8, 18 and .~~~~~~~~~~~k 1637 19. We found cytokeratins 7, 8, 15 and 18 to be expressed in fibroadenomas. This result suggests that alterations in cytokeratin expression occur early during neoplastic transformation and is consistent with the finding of low levels of cytokeratin 5 and high levels of cytokeratin 18 in immortalised breast cell lines (Trask et al., 1990) . The levels of cytokeratin 7, 8, 15 and 18 were significantly lower in carcinomas than in fibroadenomas. Decreases in cytokeratin immunostaining in breast cancer have been previously described (Wada et al., 1991; Takei et al., 1995; Heatley et al., 1995) . Takei et al. (1995) reported that cytokeratin 8 (CK8) staining was negative in 35% of invasive breast carcinomas examined, and that the absence of CK8 correlated with oestrogen receptor negativity. Similarly, Heatley et al. (1995) reported that some carcinomas are negative for cytokeratins 7, 8 Deregulation of tropomyosin expression has been shown to contribute to morphological transformation in experimental systems. It was recently suggested that Fos oncoproteins induce deregulation of genes encoding cytoskeleton-associated proteins (Jooss et al., 1995) . We have previously observed down-regulation of tropomyosin 1-3 in breast carcinoma tissue (Franzen et al., 1996) . In the present study, significant down-regulation was observed for tropomyosin 2 and 3. In one of the tumours, high tropomyosin expression was observed (see Figure 3) . Whether tropomyosin in these cells was due to contaminating, non-malignant cells or due to expression in tumour cells is not clear.
Increases in various stress proteins were found in carcinomas, but these were less than 2-fold. HSP-27 has been reported to be overexpressed in 25% of invasive ductal carcinomas, and overexpression in early-stage breast cancer is associated with poor prognosis. In addition to being induced by heat shock, HSP90 may be induced by transformation by ras (Lebeau et al., 1991) . HSP90 may also regulate DNA-binding activities of progesterone receptors in breast cancer cells. In previous studies, we observed elevated levels of HSP90 in potentially highly malignant breast tumours and in small-cell lung carcinomas (Okuzawa et al., 1994) using 2-DE.
We conclude from this study that 2-DE can be used to study complex changes in gene expression occurring in tumours. We believe that with the advent of standardised 2-DE techniques and 2-DE data bases, this approach may be a useful complement to other techniques, such as cDNA library screening.
